Compare Agnico Eagle Mines Ltd (AEM) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Pfizer Inc — how do they compare? Agnico Eagle Mines Ltd trades at $182 (market cap $91.28B), while Pfizer Inc trades at $26.62 (market cap $154.18B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| AEM | PFE | |
|---|---|---|
Market Cap | $91.28B | $154.18B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $28.56 |
52-Week Low | $130.23 | $23.60 |
Enterprise Value | $88.12B | $205.67B |
Dividend Yield | 1% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEM trades at $178.82, up 6.49% in the past 24 hours, reflecting strong momentum driven by record free cash flow and consistent earnings beats. The stock exhibits bullish technical signals with support at $177 and resistance at $181, while fundamentals show robust revenue growth to $11.91B in 2025 and a net income margin of 40.44%. Recent news highlights operational strength and gold price tailwinds.
Outlook remains positive with a consensus price target of $219.63, though risks include production costs and gold volatility. Analyst sentiment is strongly bullish with 21 buy ratings, supporting upside potential if execution continues.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
